What are the Challenges in Targeting Cancer Pathways?
Despite advancements, several challenges remain:
- Resistance: Cancer cells can develop resistance to targeted therapies through various mechanisms, such as secondary mutations or pathway activation. - Heterogeneity: Tumors are often heterogeneous, meaning they contain diverse cell populations with different genetic profiles, complicating treatment. - Toxicity: Some targeted therapies can still affect normal cells, leading to side effects.
